Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China
Compared with adjuvant chemotherapy, adjuvant icotinib may be a cost-effective treatment for resected stage II-IIIA EGFR-mutated NSCLC as the WTP threshold is set at $40 500 per QALY.
Authors
- Lifeng Mu (ORCID: https://orcid.org/0000-0001-9392-5157)
- Mei He
- Fulin Liu (ORCID: https://orcid.org/0000-0001-5176-1625)
- Yulan Fang
- Ming Yang (ORCID: https://orcid.org/0000-0001-8013-5148)
Institutions
- North Sichuan Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/bmjopen-2023-081270
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.68